When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
![Case04](https://stage.quibim.com/wp-content/uploads/2023/02/Case04-1.png?t=1676556726&ratio=1.8737997256516 1366w, https://stage.quibim.com/wp-content/uploads/2023/02/Case04-1-1250x667.png?t=1676556729&ratio=1.8740629685157 1250w, https://stage.quibim.com/wp-content/uploads/2023/02/Case04-1-625x334.png?t=1676556728&ratio=1.8712574850299 625w, https://stage.quibim.com/wp-content/uploads/2023/02/Case04-1-350x187.png?t=1676556728&ratio=1.8716577540107 350w)
![A7404974](https://stage.quibim.com/wp-content/uploads/2023/02/A7404974-2500x1667.jpg?t=1676480024&ratio=1.499700059988 2500w, https://stage.quibim.com/wp-content/uploads/2023/02/A7404974-1250x833.jpg?t=1676480022&ratio=1.500600240096 1250w, https://stage.quibim.com/wp-content/uploads/2023/02/A7404974-625x417.jpg?t=1676480020&ratio=1.4988009592326 625w, https://stage.quibim.com/wp-content/uploads/2023/02/A7404974-350x233.jpg?t=1676480019&ratio=1.5021459227468 350w)
The challenge
A prestigious Health Research Institute that has pioneered liquid biopsy analysis in colon cancer patients was interested in creating predictive and prognostic biomarkers to identify patients at high risk of relapse and predict the effect of adjuvant therapy.
Traditional methods of measuring and staging minimal residual disease (MRD) are invasive procedures. New prognostic biomarkers, such as liquid biopsy tests, even though they may improve MRD estimation, still provide limited sensitivity to identify patients at high risk of relapse.
However, the seamless integration of liquid biopsy with radiomics and deep features extracted from the CT scans (standard-of-care [SoC] data) could offer a new multi-omics tool to monitor and diagnose tumors at an early stage, providing relevant insights in the prognostic of relapse and patient outcomes.
The solution
Following a collaborative design, we collected retrospective multi-center real-world data (RWD) from a large sample of patients with confirmed diagnoses by traditional methods. The RWD included clinical data, liquid biopsy and SoC CT scans. A 3D segmentation of the tumoral tissue was performed, and textures, deep features, and fractal dimensions parameters were extracted. Once all these quantitative imaging biomarkers were obtained, several AI-based classification models were trained, combining these imaging features with liquid biopsy and clinical data to predict early relapse in patients and classify patients with low and high risk. The analysis pipeline generated was integrated into QP-Discovery® platform, creating an end-to-end AI tool.
The outcome
The innovative potential of this new approach conducted to three primary outcomes:
- The identification of the imaging signature for the early detection of relapse in localized colon cancer,
- The development of a stratification tool to differentiate between low and high-risk colon cancer patients,
- The creation of predictive models to measure the effect of adjuvant therapy that tests the antitumor efficacy of different agents, which will result in new exploitable therapeutic targets.
By merging clinical data with radiomics, fractal, and deep features, the AI model provided a high and increased accuracy of 95% (CI 95%: 85–100) when compared to clinical variables alone (55%, CI 95%: 32–78) in the prediction of relapse. A most accurate An AI-based model is expected to be obtained by combining radiomic features with RWD to predict potential patients to be relapsed, leading to the selection of personalized treatments that improve response over current standard therapies.